RPRX vs. CG, L, SYF, NTRS, CRBG, BEKE, BAM, EG, AEG, and TPG
Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include The Carlyle Group (CG), Loews (L), Synchrony Financial (SYF), Northern Trust (NTRS), Corebridge Financial (CRBG), KE (BEKE), Brookfield Asset Management (BAM), Everest Group (EG), Aegon (AEG), and TPG (TPG). These companies are all part of the "finance" sector.
Royalty Pharma (NASDAQ:RPRX) and The Carlyle Group (NASDAQ:CG) are both large-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 55.9% of The Carlyle Group shares are held by institutional investors. 18.7% of Royalty Pharma shares are held by company insiders. Comparatively, 27.0% of The Carlyle Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Royalty Pharma presently has a consensus price target of $46.75, indicating a potential upside of 68.04%. The Carlyle Group has a consensus price target of $43.07, indicating a potential downside of 7.03%. Given Royalty Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Royalty Pharma is more favorable than The Carlyle Group.
The Carlyle Group received 259 more outperform votes than Royalty Pharma when rated by MarketBeat users. However, 68.10% of users gave Royalty Pharma an outperform vote while only 57.04% of users gave The Carlyle Group an outperform vote.
Royalty Pharma has higher earnings, but lower revenue than The Carlyle Group. The Carlyle Group is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Royalty Pharma has a net margin of 48.22% compared to The Carlyle Group's net margin of -20.53%. Royalty Pharma's return on equity of 26.93% beat The Carlyle Group's return on equity.
In the previous week, The Carlyle Group had 7 more articles in the media than Royalty Pharma. MarketBeat recorded 17 mentions for The Carlyle Group and 10 mentions for Royalty Pharma. The Carlyle Group's average media sentiment score of 1.18 beat Royalty Pharma's score of 0.79 indicating that The Carlyle Group is being referred to more favorably in the news media.
Royalty Pharma pays an annual dividend of $0.84 per share and has a dividend yield of 3.0%. The Carlyle Group pays an annual dividend of $1.40 per share and has a dividend yield of 3.0%. Royalty Pharma pays out 44.4% of its earnings in the form of a dividend. The Carlyle Group pays out -82.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. The Carlyle Group is clearly the better dividend stock, given its higher yield and lower payout ratio.
Royalty Pharma has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, The Carlyle Group has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500.
Summary
Royalty Pharma and The Carlyle Group tied by winning 10 of the 20 factors compared between the two stocks.
Get Royalty Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Royalty Pharma Competitors List
Related Companies and Tools
